(Q38206818)

31 August 2017

title

Monoclonal antibodies against human cancer stem cells (English)

1 reference

31 August 2017

main subject

neoplastic stem cells

1 reference

1 reference

Cord Naujokat

1

1 reference

31 August 2017

publication date

1 January 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

6

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

290-308

1 reference

Cancer stem cells: impact, heterogeneity, and uncertainty

31 August 2017

cites work

1 reference

Cancer stem cell definitions and terminology: the devil is in the details.

21 January 2018

1 reference

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

21 January 2018

1 reference

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

21 January 2018

1 reference

Persistent malignant stem cells in del(5q) myelodysplasia in remission

21 January 2018

1 reference

A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia

21 January 2018

1 reference

let-7 regulates self renewal and tumorigenicity of breast cancer cells

21 January 2018

1 reference

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.

21 January 2018

1 reference

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

21 January 2018

1 reference

Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts

21 January 2018

1 reference

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

Trial Watch: Monoclonal antibodies in cancer therapy

21 January 2018

1 reference

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

21 January 2018

1 reference

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations

21 January 2018

1 reference

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

21 January 2018

1 reference

CD44 cell adhesion molecules

21 January 2018

1 reference

Role of CD44 in tumour progression and strategies for targeting

21 January 2018

1 reference

Cancer stem cells, microRNAs, and therapeutic strategies including natural products

21 January 2018

1 reference

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

21 January 2018

1 reference

CD44 in hematological neoplasias

21 January 2018

1 reference

CD44: a validated target for improved delivery of cancer therapeutics

21 January 2018

1 reference

Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines

21 January 2018

1 reference

The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells

21 January 2018

1 reference

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts.

21 January 2018

1 reference

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome

21 January 2018

1 reference

Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype

21 January 2018

1 reference

Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells

21 January 2018

1 reference

CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers

21 January 2018

1 reference

Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist.

21 January 2018

1 reference

Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma

21 January 2018

1 reference

Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

21 January 2018

1 reference

CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.

21 January 2018

1 reference

Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia

21 January 2018

1 reference

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

21 January 2018

1 reference

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

21 January 2018

1 reference

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

21 January 2018

1 reference

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

21 January 2018

1 reference

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

21 January 2018

1 reference

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

21 January 2018

1 reference

Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia

21 January 2018

1 reference

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

21 January 2018

1 reference

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

21 January 2018

1 reference

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.

21 January 2018

1 reference

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

21 January 2018

1 reference

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

21 January 2018

1 reference

Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population

21 January 2018

1 reference

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

21 January 2018

1 reference

Nuclear signalling by tumour-associated antigen EpCAM

21 January 2018

1 reference

EpCAM and its potential role in tumor-initiating cells

21 January 2018

1 reference

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review

21 January 2018

1 reference

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

21 January 2018

1 reference

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.

21 January 2018

1 reference

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells

21 January 2018

1 reference

Structural and functional characterization of the trifunctional antibody catumaxomab

21 January 2018

1 reference

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment

21 January 2018

1 reference

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

21 January 2018

1 reference

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial

21 January 2018

1 reference

Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

21 January 2018

1 reference

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581

21 January 2018

1 reference

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

21 January 2018

1 reference

CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges

21 January 2018

1 reference

The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells

21 January 2018

1 reference

AC133-2, a novel isoform of human AC133 stem cell antigen

21 January 2018

1 reference

The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation

21 January 2018

1 reference

Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer

21 January 2018

1 reference

Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo

21 January 2018

1 reference

Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology

21 January 2018

1 reference

The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors

21 January 2018

1 reference

Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition

21 January 2018

1 reference

Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab.

21 January 2018

1 reference

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

21 January 2018

1 reference

Targeting Notch signaling for cancer therapeutic intervention

21 January 2018

1 reference

Notch signaling in cancer stem cells

21 January 2018

1 reference

Dll4-Notch signaling as a therapeutic target in tumor angiogenesis

21 January 2018

1 reference

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency

21 January 2018

1 reference

Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.

21 January 2018

1 reference

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

21 January 2018

1 reference

Frizzled homolog proteins, microRNAs and Wnt signaling in cancer

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

21 January 2018

1 reference

Concise review: Emerging concepts in clinical targeting of cancer stem cells

21 January 2018

1 reference

Stem cells in breast tumours: are they ready for the clinic?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.14.4

1 reference

release_bohzcaqoprawdcgasi667lj56m

31 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bohzcaqoprawdcgasi667lj56m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference